1524P Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
| Autor: | Chung, V., Spira, A.I., Pavlick, A.C., Sommerhalder, D., Ma, B., Hayreh, V., de Jong, J., Funt, J., Kolitz, S., Nair, P., King, P.J., Zhang, J., Kim, J., Yamamura, A., Zeskind, B., Hall, B., Pant, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S930-S931 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|